Ryoo, Baek-Yeol

Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial

Finn, R. S., Ryoo, B.-Y., Merle, P., Kudo, M., Bouattour, M., Lim, H. Y., Breder, V., Edeline, J., Chao, Y., Ogasawara, S., et al. (2020) · Journal of Clinical Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 1,789

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Zhu, A. X., Abbas, A. R., de Galarreta, M. R., Guan, Y., Lu, S., Koeppen, H., Zhang, W., Hsu, C.-H., He, A. R., Ryoo, B.-Y., et al. (2022) · Nature Medicine

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 652

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Lee, M. S., Ryoo, B.-Y., Hsu, C.-H., Numata, K., Stein, S., Verret, W., Hack, S. P., Spahn, J., Liu, B., Abdullah, H., et al. (2020) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 562

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Kelley, R. K., Rimassa, L., Cheng, A.-L., Kaseb, A., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., et al. (2022) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 535

Randomized phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma

Abou-Alfa, G. K., Puig, O., Daniele, B., Kudo, M., Merle, P., Park, J.-W., Ross, P., Peron, J.-M., Ebert, O., Chan, S., et al. (2016) · Journal of Hepatology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 137

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): final results of a randomised phase 3 study

Yau, T., Kaseb, A., Cheng, A.-L., Qin, S., Zhu, A. X., Chan, S. L., Melkadze, T., Sukeepaisarnjaroen, W., Breder, V., Verset, G., et al. (2024) · The Lancet Gastroenterology & Hepatology

Hepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and Studies

Cited by 97

Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment

Yoo, S., Lee, D., Shim, J. H., Kim, K. M., Lim, Y.-S., Lee, H. C., Yoo, C., Ryoo, B.-Y., & Choi, J. (2022) · Clinical Gastroenterology and Hepatology

Hepatitis B Virus StudiesHepatitis C virus research

Cited by 73